Inoue H, Tsuchida A, Kawasaki Y, Fujimoto Y, Yamasaki S, Kajiyama G
First Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan.
Cancer. 2001 Jan 1;91(1):35-41. doi: 10.1002/1097-0142(20010101)91:1<35::aid-cncr5>3.0.co;2-a.
It has been reported that, in patients with intraductal papillary-mucinous tumor (IPMT) of the pancreas, it is difficult to distinguish adenoma from carcinoma preoperatively. Recently, it has also been reported that telomerase activity was detected in many patients with carcinoma. In this report, the authors used the method of telomerase repeat amplification protocol (TRAP) assay on pancreatic juice retrieved by endoscopic retrograde pancreatic juice aspiration (ERP aspiration).
Pancreatic juice was collected from 28 patients (13 with intraductal carcinoma and 15 with adenoma) using ERP aspiration at either Hiroshima University Hospital or its affiliated hospitals. Two samples of pancreatic juice were collected from each patient. Each sample was examined by cytology for Papanicolaou staining and TRAP assay.
Four of 13 IPMT patients (31%) with intraductal carcinoma were diagnosed accurately by cytology. Seven of nine patients who were classified with benign tumors by cytologic assessment had tumors that expressed telomerase activity. Overall, 11 of 13 IPMT patients (85%) with intraductal carcinoma were diagnosed correctly by cytology associated with telomerase activity. All of the IPMT patients with adenoma were classified with benign tumors by cytologic assessment, and telomerase activity was not expressed.
In this study, the authors found that telomerase activity was expressed with a comparatively high probability in intraductal carcinoma. These results suggest that telomerase activity in pancreatic juices may be used as an adjunct to cytologic diagnosis and may aid further in distinguishing between benign IPMT and malignant IPMT of the pancreas preoperatively.
据报道,在胰腺导管内乳头状黏液性肿瘤(IPMT)患者中,术前很难区分腺瘤和癌。最近,也有报道称在许多癌症患者中检测到端粒酶活性。在本报告中,作者对通过内镜逆行胰液抽吸(ERP抽吸)获取的胰液采用端粒酶重复序列扩增法(TRAP)检测。
在广岛大学医院或其附属医院,使用ERP抽吸从28例患者(13例导管内癌和15例腺瘤)中收集胰液。从每位患者收集两份胰液样本。每份样本进行巴氏染色细胞学检查和TRAP检测。
13例IPMT导管内癌患者中有4例(31%)通过细胞学检查得到准确诊断。在细胞学评估为良性肿瘤的9例患者中,有7例肿瘤表达端粒酶活性。总体而言,13例IPMT导管内癌患者中有11例(85%)通过与端粒酶活性相关的细胞学检查得到正确诊断。所有IPMT腺瘤患者通过细胞学评估均分类为良性肿瘤,且未表达端粒酶活性。
在本研究中,作者发现端粒酶活性在导管内癌中表达的概率相对较高。这些结果表明,胰液中的端粒酶活性可作为细胞学诊断的辅助手段,可能有助于术前进一步区分胰腺良性IPMT和恶性IPMT。